Osimertinib is approved by the USFDA for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy
Osimertinib is approved by the USFDA for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy